GoAI
Get started
GeoVax Labs, Inc. logo

GeoVax Labs, Inc.

GOVX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$0.6456

+$0.0436 · +7.24%

Aug 21, 4:00 PM ET

GOVX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

27

Expensive

Momentum

17

Strong Down

Sentiment

43

Mixed

Risk resilience

7

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
David Alan Dodd
Listed since
Sep 25, 2020
Employees
19

Market position

Day range

Current $0.6456

52-week range

Current $0.6456

Open
$0.6294
Previous close
$0.602
Volume
645.48K
0.13× average
Average volume
5.1M
Average daily volume
Market cap
4.76M USD
Beta
3.66
Market reference 1
50-day average
$0.9693
-33.40% below average
200-day average
$3.1767
-79.68% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.86M USD
P/E (TTM)
-0.05×
P/B (TTM)
1.67×
P/S (TTM)
0×
EV / EBITDA
-0.09×
Earnings yield
-523.26%
Free cash flow yield
-524.16%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-561.15%
Return on assets
-338.46%
Return on invested capital
-463.53%

Financial health

Debt / equity
0.18×
Current ratio
2.74×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1828%-5094%-12016%-18938%Gross margin, FY2021: -3934.79%Gross margin, FY2022: -11090.88%Gross margin, FY2024: 97.59%Gross margin, FY2025: -628.02%Operating margin, FY2021: -4862.72%Operating margin, FY2022: -17207.47%Operating margin, FY2024: -635.83%Operating margin, FY2025: -869.34%Net margin, FY2021: -4817.19%Net margin, FY2022: -17198.35%Net margin, FY2024: -631.98%Net margin, FY2025: -862.34%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -3934.79%. Gross margin FY2022 -11090.88%. Gross margin FY2024 97.59%. Gross margin FY2025 -628.02%. Operating margin FY2021 -4862.72%. Operating margin FY2022 -17207.47%. Operating margin FY2024 -635.83%. Operating margin FY2025 -869.34%. Net margin FY2021 -4817.19%. Net margin FY2022 -17198.35%. Net margin FY2024 -631.98%. Net margin FY2025 -862.34%.

Income trends

Revenue

2.49M USD-37.06%

Operating income

−21.64M USD+13.94%

Net income

−21.46M USD+14.11%
Income trends across reported periods7.02M USD−5.25M USD−17.53M USD−29.81M USDRevenue, FY2021: 385.5K USDRevenue, FY2022: 81.53K USDRevenue, FY2024: 3.95M USDRevenue, FY2025: 2.49M USDOperating income, FY2021: −18.75M USDOperating income, FY2022: −14.03M USDOperating income, FY2023: −26.74M USDOperating income, FY2024: −25.14M USDOperating income, FY2025: −21.64M USDNet income, FY2021: −18.57M USDNet income, FY2022: −14.02M USDNet income, FY2023: −25.97M USDNet income, FY2024: −24.99M USDNet income, FY2025: −21.46M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 385.5K USD. Revenue FY2022 81.53K USD. Revenue FY2024 3.95M USD. Revenue FY2025 2.49M USD. Operating income FY2021 −18.75M USD. Operating income FY2022 −14.03M USD. Operating income FY2023 −26.74M USD. Operating income FY2024 −25.14M USD. Operating income FY2025 −21.64M USD. Net income FY2021 −18.57M USD. Net income FY2022 −14.02M USD. Net income FY2023 −25.97M USD. Net income FY2024 −24.99M USD. Net income FY2025 −21.46M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.49M USD3.95M USD—81.53K USD385.5K USD
Cost of goods sold18.12M USD95.37K USD20.72M USD9.12M USD15.55M USD
Gross profit−15.63M USD3.86M USD−20.72M USD−9.04M USD−15.17M USD
Research and development18.12M USD23.71M USD20.72M USD9.12M USD15.55M USD
Selling, general, and administrative6.01M USD5.39M USD5.95M USD4.99M USD3.58M USD
Operating expenses6.01M USD29M USD6.02M USD4.99M USD3.58M USD
Interest income174.28K USD173.36K USD776.18K USD7.44K USD4.74K USD
Interest expense—21.38K USD——1.29K USD
Depreciation and amortization68.76K USD95.37K USD74.17K USD56.28K USD38.52K USD
Operating income−21.64M USD−25.14M USD−26.74M USD−14.03M USD−18.75M USD
Net income−21.46M USD−24.99M USD−25.97M USD−14.02M USD−18.57M USD

Company facts updated Aug 24, 2026.

GOVX news

GOVX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding GOVX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.19K
Weight
—
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research GOVX

research.disclaimer